Key facts
- Notable investors include Focal (San Francisco).
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for UnoBio
- ·The full record, as it builds
Funding rounds
No funding rounds for UnoBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UnoBio
Developer of an autonomous R&D engine designed to accelerate scientific discovery. The company's platform leverages AI to ingest experimental data, autonomously design and run new experiments, and return validated results, enabling research teams and biotech companies to reduce manual effort, shorten innovation cycles, and scale discovery more efficiently.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2024
- Employees
- 4
- Website
- unobio.com/
- Ownership
- Privately Held (backing)
UnoBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UnoBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UnoBio in its N-PORT filings yet. We sweep new filings monthly.